UBS Raises Price Target on Dick's Sporting Goods (DKS) Despite 4Q Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pre-Open Stock Movers 03/08: (SUNE) (XNCR) (URNB) Higher; (ACRX) (EPE) (SHAK) Lower (more...)
March 8, 2016 9:25 AM ESTSunEdison, Inc. (NYSE: SUNE) 24% HIGHER; Vivint Solar (NYSE: VSLR) announced this morning that it had delivered a letter to SunEdison, Inc. (NYSE: SUNE) last night notifying it that, as a result of SunEdison's failure to meet its obligations under the merger agreement pursuant to which the Company was to have been acquired by SunEdison, Vivint Solar has terminated such agreement. Vivint Solar reserves all rights under the merger agreement. In particular,... More
Dick's Sporting Goods (DKS) Misses Q4 EPS by 2c; Issues Light EPS Outlook
March 8, 2016 7:32 AM ESTDick's Sporting Goods (NYSE: DKS) reported Q4 EPS of $1.13, $0.02 worse than the analyst estimate of $1.15. Revenue for the quarter came in at $2.24 billion versus the consensus estimate of $2.28 billion.
Comps fell 2.5 percent.
Sees FY16 EPS of $2.85 - $3.00 and comps flat... More
After-Hours Stock Movers 03/07: (XNCR) (LNCO) (URBN) Higher; (ACRX) (SHAK) (ILMN) Lower (more...)
March 7, 2016 6:03 PM ESTXencor, Inc. (NASDAQ: XNCR) 30.4% HIGHER; announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with IgG4-Related Disease (IgG4-RD). The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE).
Linn Co, LLC (NASDAQ: LNCO) 14.6% HIGHER; adds to recent gains, including today's 109% surge.
AcelRx Pharma (NASDAQ: ACRX) 12.5% LOWER; reported Q4 EPS of ($0.24), $0.14... More
